PHARMACY

Lannett loses Jerome Stevens Pharmaceuticals supplier deal
Jerome Stevens Pharmaceuticals broke off its distribution deal with Lannett for butalbital, aspirin, caffeine with codeine phosphate capsules, digoxin tablets and levothyroxine sodium tablets.
Q&A: Opportunities and challenges facing the generics industry
Drug Store News sat down with Camber Pharmaceuticals president Kon Ostaficiuk to talk about how the company is meeting the challenges in the generics industry to better serve retailers.

Lupin receives FDA nod for two generics

Lupin received the Food and Drug Administration’s approval to launch generic PreCision Locoid lotion and Temovate cream.
Generics makers look to keep offerings competitive, affordable

One of the greatest challenges the generics industry has been facing is a product supply shortage that has been caused by a number of generics companies exiting the industry.
FDA acts to mitigate EpiPen shortages

In an effort to end recent shortages of EpiPen auto-injector, the FDA is extending the expiration date of specific lots of products marketed by Mylan.
Glenmark sets its sights on becoming a hybrid company

After focusing on the generics market, Glenmark Pharmaceuticals, whose U.S. headquarters are in Mahwah, N.J., is looking to expand its scope.
Amneal inks licensing deal for levothyroxine

Amneal will market Jerome Steven' generic levothyroxine sodium tablets for hypothyroidism and pituitary TSH suppression.
Hy-Vee pharmacies are set to give flu vaccines in store and corporate locations

Hy-Vee is stocked with flu vaccines in more than 250 of its pharmacy locations, and it is offering corporate flu clinics.
Walgreens, VA partner to improve care coordination

Through the partnership, Dept. of Veterans Affairs providers will be able to see the entire medication and immunization history of the VA-enrolled patient, if they receive prescriptions and immunizations at Walgreens.
Regeneron gets FDA nod for updated Eylea label

Regeneron Pharmaceuticals has received the green light from the Food and Drug Administration for a supplemental Biologics License Application for Eylea (aflibercept) injection in patients with wet age-related macular degeneration, or wet AMD).